Topic
alzheimer’s
22 stories related to this topic, newest first.
The Independentworld3 hrs ago
Experimental Drug Diranersen Lowers Tau but Shows Mixed Results on Cognitive Decline in Early Alzheimer’s Study
Researchers presented results Tuesday from a 400-person trial of diranersen at the Alzheimer’s Association International Conference in London. The lowest dose given every six months produced the clearest signal of reduced decline on multiple cognitive measures.
abcnews.go.comscience3 hrs ago
Biogen’s diranersen slowed cognitive decline in Phase 2 trial at rates similar to approved Alzheimer’s drugs
The experimental treatment lowered tau protein levels and produced test improvements versus placebo. Biogen said it will advance the drug to Phase 3. Experts said final judgment awaits larger trial results.
New Scientistscience9 hrs ago
Trial of THC-CBD Oil for Dementia Agitation Shows Improvement but Placebo Also Reduced Symptoms
The LiBBY trial of purified THC and CBD in a rapid-acting oil showed nearly 90 percent of 120 participants improved after 12 weeks. Results were presented at the Alzheimer’s Association International Conference but have not been peer reviewed.
New Scientistscience1 day ago
Speed-Training Game Raised Beta-Amyloid Ratio in Older Men but Showed No Effect in Women
A study of 53 adults aged 65 and older found that cognitive speed training changed blood markers of beta-amyloid in men but showed no effect in women. The results were presented on 12 July at the Alzheimer’s Association International Conference in London.
benzinga.comworld15 days ago
Case Study Reports Temporary Speech Recovery in Alzheimer’s Patient After Psilocybin Dose, Effects Later Faded
@MarioNawfal reported on a published case of an 80-year-old woman who regained speech and other functions after receiving psilocybin mushrooms. The improvements lasted days to weeks before fading.
MA
channel4.comfinance23 days ago
Former Channel 4 Presenter Jon Snow, 78, Diagnosed With Alzheimer’s
@Independent reported that former Channel 4 news presenter Jon Snow, 78, has been diagnosed with Alzheimer’s disease. His wife, epidemiologist Dr Precious Lunga, 51, discussed the diagnosis in a new Channel 4 documentary.
IN
medpagetoday.comscience24 days ago
Study Shows Amyloid Beta and Tau Compete for Microtubule Binding Sites in Nerve Cells
University of California, Riverside researchers report that amyloid beta can displace tau from microtubules inside neurons, offering one possible early mechanism in Alzheimer’s disease.
Forbesfinance26 days agoUpdated
Walter Parazaider, Co-Founder and Saxophonist of Chicago, Dies at 81
Walter Parazaider died Wednesday morning after a six-year battle with Alzheimer’s disease. The band he helped form in 1967 confirmed the news and issued condolences to his family and fans.
DA
awfulannouncing.comsports30 days ago
Ken Rosenthal wears bow tie during Phillies-Brewers broadcast after Bill Ritter’s Alzheimer’s announcement
Broadcaster Ken Rosenthal wore a bow tie on FS1 to honor New York news anchor Bill Ritter, who revealed an early-stage Alzheimer’s diagnosis.
KE
Fox Newsscience35 days ago
Case Report Finds Temporary Gains, Then Reversion, After Psilocybin in One Woman With Advanced Alzheimer’s
An elderly Japanese-American woman with advanced dementia showed restored continence, independent walking, and spontaneous conversation after two doses of psilocybin-containing mushrooms, according to a single-patient study published in Frontiers in Neuroscience.
The Independentscience36 days ago
Case Study Finds Temporary Functional Improvements, No Pathology Reversal, After High-Dose Psilocybin in Advanced Alzheimer’s Patient
An 80-year-old Japanese-American woman with advanced dementia showed short-term improvements in speech, mobility, and daily function after receiving a 5-gram dose of Enigma strain mushrooms, according to a new case study published in Frontiers in Neuroscience.
New York Postscience51 days ago
Study Links Memory Concerns and pTau181 Protein to Alzheimer’s at Age 45
Researchers analyzing data from more than 1,000 people around age 45 found that self-reported memory problems combined with elevated pTau181 protein levels may indicate Alzheimer’s risk up to two decades before typical diagnosis.
MarketWatchfinance56 days ago
Alzheimer’s Lifetime Care Costs Exceed $400,000
The lifetime cost of care for someone with Alzheimer’s disease now tops $400,000. Experts note the figure will grow as the population ages.
MA
Statscience61 days ago
Biogen Advances Tau-Targeting Alzheimer’s Drug to Phase 3 Despite Mixed Phase 2 Data
Biogen reported that its drug diranersen reduced tau levels in spinal fluid and brains of patients with early-stage Alzheimer’s in a Phase 2 trial. The reductions correlated with slower cognitive decline, though the study did not meet its primary efficacy goal of showing a dose r…
Euronewsworld63 days ago
Roche's pTau217 Blood Test Receives CE Mark for Use in Europe
Roche announced Tuesday that its Elecsys pTau217 test, the first blood test designed to signal and rule out Alzheimer’s disease, has been cleared for use across the European Union. Developed with Eli Lilly and Company, the test aims to speed diagnosis for millions facing lengthy…
Statscience63 days ago
Medicare Spending on New Alzheimer’s Drugs Falls Below Projections
Medicare payments for recently approved Alzheimer’s medications are coming in well below earlier forecasts. A spokesperson for the Centers for Medicare and Medicaid Services said uptake of the drugs has been muted and the agency is not projecting significant spending in 2026 or 2…
pharmaphorum.comscience64 days ago
Astellas to Restart Gene Therapy Trial for XLMTM Five Years After Patient Deaths Halted Program
Patients and families affected by the rare muscle disorder XLMTM are receiving a second chance at treatment as Astellas relaunches its gene therapy program. The move comes as fresh turmoil grips the top of the FDA with questions swirling over whether Commissioner Marty Makary wil…
foxnews.comscience64 days ago
Medicare Spending on Newly Approved Alzheimer’s Drugs Leqembi and Kisunla Far Below Initial Projections
Uptake of the recently approved intravenous Alzheimer’s medications has been far lower than anticipated, prompting Medicare to forecast no significant spending on Leqembi and Kisunla in 2026 or 2027. Two years ago the program projected billions of dollars annually on Leqembi alon…
Statscience64 days ago
Medicare Spending on Alzheimer’s Drugs Leqembi and Kisunla Far Below Initial Projections
Uptake of the recently approved intravenous medications has been far lower than anticipated, prompting the Centers for Medicare and Medicaid Services to project no significant spending in 2026 or 2027. The muted adoption marks a sharp reversal from projections made two years ago.
reason.comworld69 days ago
Alzheimer’s Research Scandal Highlights Problems in Scientific Oversight
A major Alzheimer’s disease research finding that influenced billions of dollars in federal funding was later found to contain manipulated images. The case has drawn attention to broader issues of research integrity, incentives in academic publishing, and oversight of taxpayer-fu…
medpagetoday.comscience89 days ago
FDA to Review Compounding Pharmacies’ Peptide Manufacturing; Alzheimer’s Drug Benefits Under Review
The FDA will hold an advisory panel meeting to consider allowing compounding pharmacies to produce certain peptides. A recent review of Alzheimer’s drugs found limited clinical benefits, though some experts noted differences among the drugs studied. Additionally, a report indicat…
PAP / Wikimedia (Public domain)world95 days ago
France Raffle Offers Picasso Portrait for 100 Euros to Support Alzheimer’s Research
A raffle in France provides an opportunity to win a 1941 Pablo Picasso portrait for a 100-euro ticket, with proceeds directed to Alzheimer’s research. The event is scheduled for Tuesday at Christie's auction house in Paris. Previous raffles in 2013 and 2020 raised over 10 million…